$CDXC News

Last published 1y ago

1y agoCDXCChromaDex Corp. Announces Name Change to Niagen Bioscience, Inc. and New Ticker Symbol "NAGE" Effective March 19, 2025Business WireChromaDex Corp. (NASDAQ:CDXC), the global authority on NAD+ (nicotinamide adenine dinucleotide) with a focus on the science of healthy aging, today announced that it will change its corporate name to Niagen Bioscience,
1y agoCDXCChromaDex to Present at the 37th Annual Roth ConferenceBusiness WireChromaDex Corp. (NASDAQ:CDXC), the global authority on nicotinamide adenine dinucleotide (NAD+) with a focus on the science of healthy aging, today announces that senior management will participate at the 37th Annual
1y agoCDXCChromaDex Corporation Reports Fourth Quarter and Fiscal Year 2024 ResultsBusiness WireFull year net sales of $99.6 million, up 19% from the prior year, gross margin of 61.8%, net income of $8.6 million, Adjusted EBITDA of $8.5 million, and $12.1 million in operating cash flows. Ended the year with $44.7
1y agoCDXCChromaDex to Report Fourth Quarter and Fiscal Year 2024 Financial Results on Tuesday, March 4, 2025Business WireChromaDex Corp. (NASDAQ:CDXC), the global authority on nicotinamide adenine dinucleotide (NAD+) research with a focus on healthy aging, announces that it will hold a conference call on Tuesday, March 4, 2025, at 4:30
1y agoCDXCChromaDex to Participate in the Lytham Partners 2025 Investor Healthcare Summit on January 13, 2025Business WireChromaDex Corp. (NASDAQ:CDXC), the global authority on nicotinamide adenine dinucleotide (NAD+) with a focus on the science of healthy aging, today announced that it will participate in a webcasted company presentation
1y agoCDXCChromaDex Named to the Inc. 2024 Best in Business List in the Health Products CategoryBusiness WireChromaDex Corp. (NASDAQ:CDXC) proudly announces its inclusion on the Inc. 2024 Best in Business list in the Health Products category. Inc.'s annual Best in Business Awards celebrate the exceptional achievements and
1y agoCDXCChromaDex's Patented Nicotinamide Riboside (NR) Ingredient, Niagen®, Featured as the Hero Ingredient in Longevity.Technology's Inaugural Longevity SupplementBusiness WireThe gold standard in NAD+ supplementation, Niagen® is a key ingredient for supporting cellular health and promoting healthy aging in Longevity.Technology's new supplement ChromaDex Corp. (NASDAQ:CDXC), the global
2y agoCDXCChromaDex's Pharmaceutical-Grade Niagen® IV Now Accessible at over 200 Restore Hyper Wellness Clinics NationwideBusiness WireNational rollout provides enhanced accessibility to Niagen IV, a significant advancement in NAD+ IV therapy ChromaDex Corp. (NASDAQ:CDXC), the global authority on nicotinamide adenine dinucleotide (NAD+) research with
2y agoCDXCChromaDex Corporation (CDXC) Q3 2024 Earnings Call TranscriptEarnings Call Transcripts
2y agoCDXCChromaDex Corporation Reports Third Quarter 2024 Financial ResultsBusiness WireTotal net sales of $25.6 million, up $6.1 million or 31% year-over-year, gross margin of 63.5% and record net income and adjusted EBITDA of $1.9 million and $2.9 million, respectively, for the three months ended
2y agoCDXCChromaDex to Report Third Quarter 2024 Financial Results on Thursday, October 31, 2024Business WireChromaDex Corp. (NASDAQ:CDXC), the global authority on nicotinamide adenine dinucleotide (NAD+) research with a focus on healthy aging, announced that it has rescheduled its previously announced conference call to
2y agoCDXCChromaDex to Report Third Quarter 2024 Financial Results on Thursday, October 31, 2024Business WireChromaDex Corp. (NASDAQ:CDXC), the global authority on nicotinamide adenine dinucleotide (NAD+) research with a focus on healthy aging, announced that it will hold a conference call on Wednesday, November 6, 2024 at
2y agoCDXCChromaDex to Participate in the 17th Annual LD Micro Main EventBusiness WireChromaDex Corp. (NASDAQ:CDXC), the global authority on nicotinamide adenine dinucleotide (NAD+) research with a focus on healthy aging, announced that it will be participating at the 17th Annual LD Micro Main Event at
2y agoCDXCYasmeen Nkrumah-Elie, Ph.D., Global Director of External Research at ChromaDex, Honored with the Trailblazing Woman Award by Radicle Science and Council for Responsible Nutrition (CRN)Business WireThis award recognizes Dr. Nkrumah-Elie's dedication to advancing scientific excellence for ChromaDex's leading external research program and mentorship in the dietary supplement industry ChromaDex Corp. (NASDAQ:CDXC),
2y agoCDXCChromaDex to Participate in a Fireside Chat at the Lytham Partners Fall 2024 Investor ConferenceBusiness WireChromaDex Corp. (NASDAQ:CDXC), the global authority on nicotinamide adenine dinucleotide (NAD+) with a focus on healthy-aging research, today announced that Rob Fried, CEO of ChromaDex and Founder of Tru Niagen, will
2y agoCDXCChromaDex Appoints Ozan Pamir as Chief Financial OfficerBusiness WireChromaDex Corp. (NASDAQ:CDXC), the global authority on nicotinamide adenine dinucleotide (NAD+) research with a focus on healthy aging, announces the appointment of Ozan Pamir as Chief Financial Officer. Mr. Pamir will
2y agoCDXCChromaDex Announces Expansion of Pharmaceutical-Grade Niagen® IV and Injection Offerings to Additional Leading Wellness ClinicsBusiness WireU.S. FDA-registered 503B outsourcing facility, Wells Pharma of Houston, will compound and distribute Niagen (nicotinamide riboside chloride) IV and injections to 14 new clinics ChromaDex Corp. (NASDAQ:CDXC), the global
2y agoCDXCChromaDex Celebrates 25 Years of Innovation and Pioneering NAD+ Research for Healthy Aging SolutionsBusiness WireCommemorating a quarter of a century with an exclusive 25% off lifelong subscription on Tru Niagen® ChromaDex Corp. (NASDAQ:CDXC), the global authority on nicotinamide adenine dinucleotide (NAD+) research with a
2y agoCDXCChromaDex to Participate in Renmark's Virtual Non-Deal Roadshow Series On Thursday, August 29, 2024Business WireChromaDex Corp. (NASDAQ:CDXC), the global authority on nicotinamide adenine dinucleotide (NAD+) research with a focus on healthy aging, announced today that they will be participating in Renmark Financial Communications
2y agoCDXCChromaDex Secures U.S. Patent for the Composition of Matter of Salt Forms of NMNH (Dihydronicotinamide Mononucleotide), a Precursor to NAD+Business WireOne of the most robust forms of intellectual property protection, a composition of matter patent grants ChromaDex exclusive rights to the disodium salt form of NMNH ChromaDex Corp. (NASDAQ:CDXC), the global authority
2y agoCDXCChromaDex Corporation Reports Second Quarter 2024 Financial ResultsBusiness WireTotal net sales of $22.7 million, up 12% year-over-year, gross margin of 60.2%, lower operating expenses, resulting in approximately breakeven net loss and positive Adjusted EBITDA of $1.6 million for the three months
2y agoCDXCChromaDex to Present at Canaccord Genuity's 44th Annual Growth ConferenceBusiness WireChromaDex Corp. (NASDAQ:CDXC), the global authority on nicotinamide adenine dinucleotide (NAD+) research with a focus on healthy aging, today announced that its Chief Executive Officer, Rob Fried, and Interim Chief
2y agoCDXCChromaDex to Report Second Quarter 2024 Financial Results on Wednesday, August 7, 2024Business WireChromaDex Corp. (NASDAQ:CDXC), the global authority on nicotinamide adenine dinucleotide (NAD+) research with a focus on healthy aging, announced that it will hold a conference call on Wednesday, August 7, 2024 at 4:30
2y agoCDXCChromaDex Launches Niagen+ NAD+ Test Kit Available Exclusively to Health Care Practitioners (HCPs)Business WireResults from the at-home test kit are available to HCPs and their patients through 1health ChromaDex Corp. (NASDAQ:CDXC), the global authority on nicotinamide adenine dinucleotide (NAD+) research with a focus on
2y agoCDXCChromaDex Appoints Carlos Lopez as Senior Vice President, General CounselBusiness WireChromaDex Corp. (NASDAQ:CDXC), the global authority on nicotinamide adenine dinucleotide (NAD+) research with a focus on healthy aging, announces the appointment of Carlos Lopez as Senior Vice President, General
2y agoCDXCChromaDex Announces Pharmaceutical-Grade Intravenous and Injectable Niagen® Will Debut at Leading Wellness Clinics in AugustBusiness WireU.S. FDA-registered 503B outsourcing facility, Wells Pharma of Houston, will compound and distribute Niagen (nicotinamide riboside chloride) IV and injections to Cenegenics, Clean Market/NutriDrip, Drip Hydration, EXTEN
2y agoCDXCChromaDex to Join Russell 2000® IndexBusiness WireChromaDex continues to drive innovation and growth with its proprietary Tru Niagen® supplement, backed by strong financial performance and a robust intellectual property portfolio ChromaDex Corp. (NASDAQ:CDXC),
2y agoCDXCMilestone Phase II Clinical Study Demonstrates Niagen®, Patented Nicotinamide Riboside (NR), Improves Functional Mobility for Individuals with Peripheral Artery Disease (PAD)Business WireNR improved the six-minute walking distance and treadmill walking time for those with PAD ChromaDex Corp. (NASDAQ:CDXC), the global authority on nicotinamide adenine dinucleotide (NAD+) research, shares results from a
2y agoCDXCChromaDex to Launch Niagen+, the First-Of-Its-Kind Pharmaceutical-Grade Intravenous and Injectable Niagen® (Patented Nicotinamide Riboside Chloride or NRC)Business WireClinical study results demonstrated that Niagen IV had no adverse side effects, provided superior tolerability, and a 75% shorter infusion time, with blood NAD+ levels peaking sooner and higher three hours post-infusion
2y agoCDXCChromaDex Receives Exclusive U.S. FDA Orphan Drug Designation (ODD) and Rare Pediatric (RPD) Disease Designation for Nicotinamide Riboside Chloride (NRC) for the Treatment of Ataxia Telangiectasia (AT)Business WireChromaDex plans to conduct additional studies on NRC in anticipation of filing for an Investigational New Drug Application (IND) for the treatment of AT ChromaDex Corp. (NASDAQ:CDXC), the global authority on
2y agoCDXCChromaDex to Participate in Renmark's Virtual Non-Deal Roadshow on Tuesday, June 11, 2024Business WireChromaDex Corp. (NASDAQ:CDXC), the global authority on nicotinamide adenine dinucleotide (NAD+) and healthy aging research, announced today that it will be participating in Renmark Financial Communications Inc.'s live
2y agoCDXCChromaDex to Participate in the Lytham Partners Spring 2024 Investor Conference on May 30, 2024Business WireChromaDex Corp. (NASDAQ:CDXC), the global authority on nicotinamide adenine dinucleotide (NAD+) and healthy-aging research, today announced that its Chief Executive Officer, Rob Fried, and Chief Financial Officer,
2y agoCDXCChromaDex's Niagen® Wins Prestigious NutraIngredients EU Healthy Ageing Ingredient of the Year AwardBusiness WireJudges award Niagen for its "high-quality, unparalleled" healthy aging research ChromaDex Corp. (NASDAQ:CDXC), the global authority on nicotinamide adenine dinucleotide (NAD+) and healthy aging research, is proud to
2y agoCDXCChromaDex Corporation (CDXC) Q1 2024 Earnings Call TranscriptEarnings Call Transcripts
2y agoCDXCChromaDex Corporation Reports First Quarter 2024 Financial ResultsBusiness WireTotal net sales of $22.2 million, gross margin of 60.7%, a net loss of $0.5 million and a positive Adjusted EBITDA of $0.7 million for the three months ended March 31, 2024. Reiterated full year outlook including net
2y agoCDXCChromaDex's NIAGEN® (Patented Nicotinamide Riboside, NR), the Most Efficient and High-Quality NAD+ Precursor, Featured in New Solgar® Cellular Nutrition Cellular Energy SupplementBusiness WireNew ingredient collaboration debuts Solgar's first NAD+ boosting supplement and reinforces NIAGEN as the gold standard in the NAD+ supplement category ChromaDex Corp. (NASDAQ:CDXC), the global authority on
2y agoCDXCChromaDex Announces Nationwide Launch of Tru Niagen® at The Vitamin Shoppe®Business WireTru Niagen is now available at 700 retail locations of The Vitamin Shoppe and Super Supplements™ and online at vitaminshoppe.com ChromaDex Corp. (NASDAQ:CDXC), the global authority on nicotinamide adenine
2y agoCDXCChromaDex to Report First Quarter 2024 Financial Results on Wednesday, May 8, 2024Business WireChromaDex Corp. (NASDAQ:CDXC), the global authority on nicotinamide adenine dinucleotide (NAD+) and healthy aging research, announced that it will hold a conference call on Wednesday, May 8, 2024 at 4:30 p.m. ET to
2y agoCDXCChromaDex Announces Inaugural Major Grocery Debut of Tru Niagen® at Sprouts Farmers MarketBusiness WireTru Niagen® expands to health-conscious Sprouts consumers in more than 400 locations across 23 states ChromaDex Corp. (NASDAQ:CDXC), the global authority on nicotinamide adenine dinucleotide (NAD+) and healthy
2y agoCDXCChromaDex Announces Tru Niagen® is Now Third-Party Verified Through the Alkemist Assured™ Transparency ProgramBusiness WireAll Tru Niagen products (except Tru Niagen 1,000mg, which is NSF Certified for Sport®) are Alkemist Assured ChromaDex Corp. (NASDAQ:CDXC), the global authority on nicotinamide adenine dinucleotide (NAD+) and
2y agoCDXCChromaDex Corporation (CDXC) Q4 2023 Earnings Call TranscriptEarnings Call Transcripts
2y agoCDXCChromaDex Corporation Reports Fourth Quarter and Fiscal Year 2023 ResultsBusiness WireFourth quarter net sales of $21.2 million, gross margin of 61.0%, and net income of $0.1 million. Full year net sales of $83.6 million, up 16% from the prior year, gross margin of 60.8%, net loss of only $4.9 million,
2y agoCDXCChromaDex to Report Fourth Quarter 2023 Financial Results on Wednesday, March 6, 2024Business WireChromaDex Corp. (NASDAQ:CDXC) ("the Company"), a global bioscience company dedicated to healthy aging, announced that it will hold a conference call on Wednesday, March 6, 2024 at 4:30 p.m. ET to discuss its financial
2y agoCDXCChromaDex to Participate in Renmark's Virtual Non-Deal Roadshow on Monday, February 12, 2024Business WireChromaDex Corp. (NASDAQ:CDXC), the global authority on nicotinamide adenine dinucleotide (NAD+) and healthy aging research, announced today that it will be participating in Renmark Financial Communications Inc.'s live
2y agoCDXCChromaDex to Present at the Lytham Partners 2024 Investor Select ConferenceBusiness WireChromaDex Corp. (NASDAQ:CDXC), the global authority on nicotinamide adenine dinucleotide (NAD+) and healthy aging research, today announced that its Chief Executive Officer, Rob Fried, and Chief Financial Officer,
2y agoCDXCChromaDex Supports the US Military with its Industry Leading NAD+ Supplement, Tru Niagen®Business WireTru Niagen is now available to US troops through an exclusive Military program ChromaDex Corp. (NASDAQ:CDXC), the global authority on nicotinamide adenine dinucleotide (NAD+) and healthy aging research, is proud to
2y agoCDXCNeurohacker Collective and ChromaDex Partner to Optimize Cellular Health with the Debut of Qualia NAD+PR NewswireNeurohacker Collective, an acclaimed American science team that has been formulating advanced nutritional supplements since 2015, has just created an ...
2y agoCDXCA Milestone Phase I Randomized, Double-Blind Clinical Trial Demonstrates High-Dose Niagen®, Patented Nicotinamide Riboside (NR), Supplementation Induces a Potent NAD+ Response and Is Associated With Mild Improvement in Parkinson's Disease (PD)Business WireBuilding on a growing body of research showcasing NR as a potential therapeutic strategy for PD, this is the first clinical study to showcase the safety, tolerability, and beneficial metabolic effects of high-dose NR at
2y agoCDXCNewly Published Phase II Clinical Study Demonstrates that Supplementation with Niagen®, Patented Nicotinamide Riboside (NR), Elevates NAD+ Up to Fourfold, Improving Motor Coordination and Eye Movement in Ataxia Telangiectasia (AT) PatientsBusiness WireThis is the longest Niagen NR clinical trial to date spanning two years and showcases that long-term Niagen NR is safe and well tolerated ChromaDex Corp. (NASDAQ:CDXC), one of the global authorities on Nicotinamide
3y agoCDXCChromaDex to Participate in Renmark's Virtual Non-Deal Roadshow on Tuesday, November 14, 2023Business WireChromaDex Corporation (NASDAQ:CDXC), a global authority on Nicotinamide Adenine Dinucleotide (NAD+) and healthy aging research, announced today that they will be participating in Renmark Financial Communications Inc.'s